

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
2	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	EPA+DHA	Intake	No
3	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	EPA+DHA	Intake	No
4	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	EPA+DHA	Intake	No
5	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	EPA+DHA	Intake	No
6	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	ALA	Intake	No
7	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	ALA	Intake	No
8	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	ALA	Intake	No
9	Belin 2011 21610249	Women's Health Initiative	CHF	incident HF	Healthy	Women, 50-79 y, Healthy	All	1858/84493 (2.2)	10 y	ALA	Intake	No
10	Brouwer 2006 16569549	Rotterdam	CHF	shortness of breath, ankle oedema, and pulmonary crepitation	Healthy	ppl who had no heart failure at baseline	All	669/5299 (12.6)	11.4 y	EPA+DHA	Intake	Yes
11	Brouwer 2006 16569549	Rotterdam	CHF	shortness of breath, ankle oedema, and pulmonary crepitation	Healthy	ppl who had no heart failure at baseline	All	669/5299 (12.6)	11.4 y	EPA+DHA	Intake	Yes
12	Brouwer 2006 16569549	Rotterdam	CHF	shortness of breath, ankle oedema, and pulmonary crepitation	Healthy	ppl who had no heart failure at baseline	All	669/5299 (12.6)	11.4 y	EPA+DHA	Intake	Yes
13	Brouwer 2006 16569549	Rotterdam	CHF	shortness of breath, ankle oedema, and pulmonary crepitation	Healthy	ppl who had no heart failure at baseline	All	669/5299 (12.6)	11.4 y	EPA+DHA	Intake	Yes
14	Brouwer 2006 16569549	Rotterdam	CHF	shortness of breath, ankle oedema, and pulmonary crepitation	Healthy	ppl who had no heart failure at baseline	All	669/5299 (12.6)	11.4 y	EPA+DHA	Intake	Yes
15	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	All	nd/671	4 y	DHA	Blood	No
16	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	All	nd/671	4 y	DHA	Blood	No
17	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	All	nd/671	4 y	DHA	Blood	No
18	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	All	nd/671	4 y	EPA	Blood	No
19	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	All	nd/671	4 y	EPA	Blood	No
20	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	All	nd/671	4 y	EPA	Blood	No
21	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	ALA	Intake	yes
22	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	ALA	Intake	yes

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
2	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr1	g/d	0	nd
3	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr2	g/d	0.048	nd
4	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr3	g/d	0.093	nd
5	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr4	g/d	>0.163	nd
6	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr1	g/d	0	nd
7	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr2	g/d	0.711	nd
8	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr3	g/d	1.02	nd
9	Belin 2011 21610249	age, ethnicity, education, physical activity, smoking, alcohol diabetes, hypertension, AF, MI/CABG/PTCA, BMI, time-dependent MI	Qr4	g/d	>1.465	nd
10	Brouwer 2006 16569549	age, sex, total energy intake, smoking, BMI, education, and alcohol intake.	Qt1	mg/d	nd	14
11	Brouwer 2006 16569549	age, sex, total energy intake, smoking, BMI, education, and alcohol intake.	Qt2	mg/d	28	42
12	Brouwer 2006 16569549	age, sex, total energy intake, smoking, BMI, education, and alcohol intake.	Qt3	mg/d	62	89
13	Brouwer 2006 16569549	age, sex, total energy intake, smoking, BMI, education, and alcohol intake.	Qt4	mg/d	121	161
14	Brouwer 2006 16569549	age, sex, total energy intake, smoking, BMI, education, and alcohol intake.	Qt5	mg/d	213	313
15	Hara 2013 23047296	Propensity score	T1	mcg/mL	nd	nd
16	Hara 2013 23047296	Propensity score	T2	mcg/mL	61.4	nd
17	Hara 2013 23047296	Propensity score	T3	mcg/mL	83.5	nd
18	Hara 2012 23047296	Propensity score	T1	mcg/mL	nd	nd
19	Hara 2012 23047296	Propensity score	T2	mcg/mL	24.6	nd
20	Hara 2012 23047296	Propensity score	T3	mcg/mL	38.8	nd
21	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt1	g/d	nd	mean 0.86 (0.09)
22	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt2	g/d	nd	mean 1.03 (0.04)

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
2	Belin 2011 21610249	<0.048	HR	510	21013		Reference group			P trend	0.29
3	Belin 2011 21610249	0.092		492	21252		0.95	0.84	1.08		
4	Belin 2011 21610249	0.163		435	21051		0.91	0.8	1.03		
5	Belin 2011 21610249	nd		421	21177		0.95	0.83	1.08		
6	Belin 2011 21610249	<0.711	HR	443	21238		Reference group			P trend	0.773
7	Belin 2011 21610249	1.019		464	21092		1.06	0.93	1.2		
8	Belin 2011 21610249	1.465		468	21155		1.03	0.9	1.17		
9	Belin 2011 21610249	nd		483	21008		1.03	0.9	1.17		
10	Brouwer 2006 16569549	27	RR	155	1060	11715	1			P trend	0.22
11	Brouwer 2006 16569549	61	RR	135	1060	12006	0.95	0.75	1.2		
12	Brouwer 2006 16569549	120	RR	142	1060	12048	0.98	0.77	1.23		
13	Brouwer 2006 16569549	212	RR	120	1060	12234	0.84	0.66	1.07		
14	Brouwer 2006 16569549	nd	RR	117	1060	10097	0.88	0.69	1.12		
15	Hara 2013 23047296	61.4	HR	nd	239	nd	0.581395349	0.289855072	1.162790698	T2-3 vs. T1	0.1224
16	Hara 2013 23047296	83.5		nd	236	nd					
17	Hara 2013 23047296	nd		nd	237	nd					
18	Hara 2012 23047296	24.6	HR	nd	237	nd	0.416666667	0.210526316	0.826446281	T2-3 vs. T1	0.0097
19	Hara 2012 23047296	38.8		nd	237	nd					
20	Hara 2012 23047296	nd		nd	238	nd					
21	Levitan 2010 20332801	nd	RR	168	nd	61959	Reference group			P trend	0.41
22	Levitan 2010 20332801	nd		123	nd	62897	1.1	0.87	1.38		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
23	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	ALA	Intake	yes
24	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	ALA	Intake	yes
25	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	ALA	Intake	yes
26	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	EPA+DHA	Intake	yes
27	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	EPA+DHA	Intake	yes
28	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	EPA+DHA	Intake	yes
29	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	EPA+DHA	Intake	yes
30	Levitan 2010 20332801	Swedish Mammography Study	CHF	Heart failure hospitalization or mortality	Healthy	Healthy, ages 49-83	All	651/36234 (1.8)	9 y	EPA+DHA	Intake	yes
31	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	686/2957 (23.2)	16y	ALA	Plasma	no
32	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	686/2957 (23.2)	16y	ALA	Plasma	no
33	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	686/2957 (23.2)	16y	ALA	Plasma	no
34	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	686/2957 (23.2)	16y	ALA	Plasma	no
35	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DPA	Plasma	no
36	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DPA	Plasma	no
37	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DHA	Plasma	no
38	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DHA	Plasma	no

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
23	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt3	g/d	nd	mean 1.15 (0.03)
24	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt4	g/d	nd	mean 1.28 (0.04)
25	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt5	g/d	nd	mean 1.56 (0.22)
26	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt1	g/d	0.01	0.14
27	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt2	g/d	0.2	0.23
28	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt3	g/d	0.28	0.3
29	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt4	g/d	0.34	0.38
30	Levitan 2010 20332801	We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fiber consumption (linear), sodium consumption (linear), daily servings of red or processed meat (linear), education (less than high school, high school, university), family history of myocardial infarction at <60 years (yes, no), cigarette smoking (current, past, never), living alone (yes, no), postmenopausal hormone use (yes, no), self-reported history of hypertension (yes, no) and self-reported history of high cholesterol (yes, no).	Qt5	g/d	0.46	0.57
31	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr1	% FA	0.05	0.09 (mean)
32	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr2	% FA	0.11	0.13 (mean)
33	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr3	% FA	0.14	0.16 (mean)
34	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr4	% FA	0.18	0.22 (mean)
35	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr3	% FA	0.82	0.88 (mean)
36	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr4	% FA	0.94	1.06 (mean)
37	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr1	% FA	1.07	1.98 (mean)
38	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr2	% FA	2.34	2.6 (mean)

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
23	Levitan 2010 20332801	nd		99	nd	63153	0.99	0.77	1.26		
24	Levitan 2010 20332801	nd		120	nd	63064	1.05	0.82	1.33		
25	Levitan 2010 20332801	nd		141	nd	62146	0.91	0.71	1.17		
26	Levitan 2010 20332801	0.19	RR	168	nd	61959	Reference group			P linear trend	0.04
27	Levitan 2010 20332801	0.27		123	nd	62847	0.85	0.67	1.07		
28	Levitan 2010 20332801	0.33		99	nd	63153	0.79	0.61	1.02		
29	Levitan 2010 20332801	0.45		120	nd	63064	0.83	0.65	1.06		
30	Levitan 2010 20332801	7.15		141	nd	62146	0.75	0.58	0.96		
31	Lemaitre 2012 22743310	0.11	HR	191	nd	7838	Reference group			P trend	0.85
32	Lemaitre 2012 22743310	0.14	HR	169	nd	7570	0.97	0.78	1.2		
33	Lemaitre 2012 22743310	0.18	HR	161	nd	7469	0.98	0.79	1.22		
34	Lemaitre 2012 22743310	0.47	HR	165	nd	7864	0.97	0.79	1.21		
35	Mozaffarian 2011 21810709	0.93	HR	131	nd	6732	0.73	0.53	1		
36	Mozaffarian 2011 21810709	1.63	HR	132	nd	6635	0.76	0.56	1.04		
37	Mozaffarian 2011 21810709	2.33	HR	141	nd	6533	Reference group			P trend	0.38
38	Mozaffarian 2011 21810709	2.86	HR	144	nd	6415	0.9	0.66	1.21		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
39	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DHA	Plasma	no
40	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	EPA	Plasma	no
41	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	EPA	Plasma	no
42	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	EPA	Plasma	no
43	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	EPA	Plasma	no
44	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DPA	Plasma	no
45	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DPA	Plasma	no
46	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	1072/4432 (24.2)	12y	ALA	Intake	no
47	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	1072/4432 (24.2)	12y	ALA	Intake	no
48	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	1072/4432 (24.2)	12y	ALA	Intake	no
49	Lemaitre 2012 22743310	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	1072/4432 (24.2)	12y	ALA	Intake	no
50	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	DHA	Plasma	no
51	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	All n-3	Plasma	no
52	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	All n-3	Plasma	no
53	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	All n-3	Plasma	no
54	Mozaffarian 2011 21810709	Cardiovascular Health Study	CHF	incident CHF	Healthy	Healthy age >= 65y	All	555/2735 (20.3)	14y	All n-3	Plasma	no
55	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	All	nd/44601	7 y	EPA+DHA	Intake	No
56	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	All	nd/44601	7 y	EPA+DHA	Intake	No
57	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	All	nd/44601	7 y	EPA+DHA	Intake	No
58	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	All	nd/44601	7 y	EPA+DHA	Intake	No

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
39	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr3	% FA	2.87	3.17 (mean)
40	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr1	% FA	0.11	0.31 (mean)
41	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr2	% FA	0.39	0.45 (mean)
42	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr3	% FA	0.51	0.59 (mean)
43	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr4	% FA	0.69	1.04 (mean)
44	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr1	% FA	0.11	0.62 (mean)
45	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr2	% FA	0.72	0.77 (mean)
46	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr1	% fat intake	nd	nd
47	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr2	% fat intake	nd	nd
48	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr3	% fat intake	nd	nd
49	Lemaitre 2012 22743310	age (y) and sex, enrollment site (4 sites), race (white, nonwhite), education (high school, high school, college), smoking (never, former, current), leisure-time physical activity (kcal/wk), BMI (kg/m2), waist circumference (cm), and alcohol consumption (g/d).	Qr4	% fat intake	nd	nd
50	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr4	% FA	3.55	4.39 (mean)
51	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr1	% FA	nd	nd
52	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr2	% FA	nd	nd
53	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr3	% FA	nd	nd
54	Mozaffarian 2011 21810709	Adjusted for age, sex, race (white or nonwhite), education (less than high school, high school, some college, or college graduate), enrollment site, smoking status (never, former, or current), prevalent diabetes (yes or no), prevalent atrial fibrillation (yes or no), leisure-time physical activity, body mass index, waist circumference, and alcohol use (6 categories).	Qr4	% FA	nd	nd
55	Leviton 2009 19383731	nd	Qt1	g/d	nd	nd
56	Leviton 2009 19383731	nd	Qt2	g/d	nd	nd
57	Leviton 2009 19383731	nd	Qt3	g/d	nd	nd
58	Leviton 2009 19383731	nd	Qt4	g/d	nd	nd

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
39	Mozaffarian 2011 21810709	3.54	HR	143	nd	6794	0.91	0.67	1.25		
40	Mozaffarian 2011 21810709	0.38	HR	174	nd	6198	Reference group			P trend	0.001
41	Mozaffarian 2011 21810709	0.5	HR	131	nd	6503	0.61	0.45	0.83		
42	Mozaffarian 2011 21810709	0.68	HR	126	nd	6993	0.65	0.47	0.9		
43	Mozaffarian 2011 21810709	8.52	HR	124	nd	6797	0.52	0.38	0.72		
44	Mozaffarian 2011 21810709	0.71	HR	147	nd	6540	Reference group			P trend	0.057
45	Mozaffarian 2011 21810709	0.81	HR	145	nd	6583	0.89	0.66	1.22		
46	Lemaitre 2012 22743310	nd	HR	319	nd	12753	Reference group			P trend	0.97
47	Lemaitre 2012 22743310	nd	HR	280	nd	13472	0.83	0.71	0.98		
48	Lemaitre 2012 22743310	nd	HR	258	nd	13387	0.92	0.77	1.09		
49	Lemaitre 2012 22743310	nd	HR	215	nd	12997	0.99	0.82	1.2		
50	Mozaffarian 2011 21810709	8.17	HR	127	nd	6750	0.84	0.58	1.21		
51	Mozaffarian 2011 21810709	nd	HR	143	nd	6379	Reference group			P trend	0.062
52	Mozaffarian 2011 21810709	nd	HR	153	nd	6605	0.82	0.61	1.11		
53	Mozaffarian 2011 21810709	nd	HR	135	nd	6595	0.8	0.58	1.1		
54	Mozaffarian 2011 21810709	nd	HR	124	nd	6912	0.7	0.49	0.99		
55	Levitan 2009 19383731	nd	HR	nd	nd	nd	Reference group				NS (implied)
56	Levitan 2009 19383731	nd		nd	nd	nd	0.98	0.6	1.58		
57	Levitan 2009 19383731	nd		nd	nd	nd	0.84	0.49	1.43		
58	Levitan 2009 19383731	nd		nd	nd	nd	1.27	0.77	2.09		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
59	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	All	nd/44601	7 y	EPA+DHA	Intake	No
60	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	EPA+DHA+DPA	Intake	explicitly excluded fish oil supplements
61	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	EPA+DHA+DPA	Intake	explicitly excluded fish oil supplements
62	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	EPA+DHA+DPA	Intake	explicitly excluded fish oil supplements
63	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	EPA+DHA+DPA	Intake	explicitly excluded fish oil supplements
64	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	EPA+DHA+DPA	Intake	explicitly excluded fish oil supplements
65	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	ALA	Intake	explicitly excluded fish oil supplements
66	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	ALA	Intake	explicitly excluded fish oil supplements
67	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	ALA	Intake	explicitly excluded fish oil supplements
68	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	ALA	Intake	explicitly excluded fish oil supplements
69	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	703/19097 (3.68)	4 y	ALA	Intake	explicitly excluded fish oil supplements
70	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	EPA+DHA+DPA	Plasma	explicitly excluded fish oil supplements
71	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	EPA+DHA+DPA	Plasma	explicitly excluded fish oil supplements
72	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	EPA+DHA+DPA	Plasma	explicitly excluded fish oil supplements
73	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	EPA+DHA+DPA	Plasma	explicitly excluded fish oil supplements
74	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	EPA+DHA+DPA	Plasma	explicitly excluded fish oil supplements
75	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	ALA	Plasma	explicitly excluded fish oil supplements

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
59	Levitan 2009 19383731	nd	Qt5	g/d	nd	nd
60	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T1	g/d	nd	0.079
61	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T2	g/d	nd	nd
62	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T3	g/d	nd	0.152
63	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T4	g/d	nd	nd
64	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T5	g/d	nd	0.397
65	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T1	g/d	nd	0.576
66	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T2	g/d	nd	nd
67	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T3	g/d	nd	0.765
68	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T4	g/d	nd	nd
69	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T5	g/d	nd	1
70	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T1	% FA	nd	3.204
71	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T2	% FA	nd	nd
72	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T3	% FA	nd	4.412
73	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T4	% FA	nd	nd
74	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T5	% FA	nd	6.458
75	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T1	% FA	nd	0.097

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
59	Levitan 2009 19383731	nd		nd	nd	nd	1.19	0.75	1.91		
60	Wilk 2012 22952185	nd	HR	172		31310	1			P trend	0.12
61	Wilk 2012 22952185	nd	HR	151		32151	0.92	0.74	1.14		
62	Wilk 2012 22952185	nd	HR	124		32171	0.84	0.66	1.06		
63	Wilk 2012 22952185	nd	HR	123		32550	0.81	0.64	1.02		
64	Wilk 2012 22952185	nd	HR	133		32113	0.94	0.75	1.18		
65	Wilk 2012 22952185	nd	HR	157		31772	1			P trend	0.32
66	Wilk 2012 22952185	nd	HR	137		32074	0.82	0.65	1.03		
67	Wilk 2012 22952185	nd	HR	131		32302	0.79	0.63	1		
68	Wilk 2012 22952185	nd	HR	138		32186	0.82	0.65	1.03		
69	Wilk 2012 22952185	nd	HR	140		31961	0.83	0.66	1.05		
70	Wilk 2012 22952185	nd	OR	151			1			P trend	0.17
71	Wilk 2012 22952185	nd	OR	182			1.26	0.9	1.75		
72	Wilk 2012 22952185	nd	OR	174			1.18	0.85	1.64		
73	Wilk 2012 22952185	nd	OR	145			0.97	0.69	1.38		
74	Wilk 2012 22952185	nd	OR	134			0.92	0.64	1.33		
75	Wilk 2012 22952185	nd	OR	205			1			P trend	0.03

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
76	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	ALA	Plasma	explicitly excluded fish oil supplements
77	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	ALA	Plasma	explicitly excluded fish oil supplements
78	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	ALA	Plasma	explicitly excluded fish oil supplements
79	Wilk 2012 22952185	Physician's Health Study	CHF	nd	Healthy	US male physicians	All	786/19097 (4.12)	4 y	ALA	Plasma	explicitly excluded fish oil supplements
80	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Cholesterol ester	Yes
81	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Cholesterol ester	Yes
82	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Cholesterol ester	Yes
83	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Cholesterol ester	Yes
84	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Cholesterol ester	Yes
85	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Phospholipid	Yes
86	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Phospholipid	Yes
87	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Phospholipid	Yes
88	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Phospholipid	Yes
89	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	ALA	Phospholipid	Yes
90	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Cholesterol ester	Yes
91	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Cholesterol ester	Yes
92	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Cholesterol ester	Yes

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
76	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T2	% FA	nd	nd
77	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T3	% FA	nd	0.143
78	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T4	% FA	nd	nd
79	Wilk 2012 22952185	age, atrial fibrillation, hypertension, BMI, alcohol, current smoking, former smoking, exercise, and valvular heart disease	T5	% FA	nd	0.306
80	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.269029328
81	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.352315944
82	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean	0.41
83	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	0.467684056
84	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	0.550970672
85	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.075922422
86	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.113779974
87	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean	0.14
88	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	0.166220026
89	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	0.204077578
90	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.191165562
91	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.403167856
92	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean	0.55

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
76	Wilk 2012 22952185	nd	OR	158			0.76	0.55	1.05		
77	Wilk 2012 22952185	nd	OR	145			0.71	0.5	1		
78	Wilk 2012 22952185	nd	OR	125			0.66	0.47	0.94		
79	Wilk 2012 22952185	nd	OR	153			0.84	0.56	1.26		
80	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.22
81	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.2	0.77	1.88		
82	Yamagishi 2008 19061714	SD 0.11	HR	nd	nd	nd	0.84	0.53	1.34		
83	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.41	0.91	2.19		
84	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.27	0.8	2.02		
85	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.17
86	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.07	0.68	1.71		
87	Yamagishi 2008 19061714	SD 0.05	HR	nd	nd	nd	1.3	0.86	1.97		
88	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.13	0.71	1.8		
89	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.44	0.88	2.35		
90	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.51
91	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.46	0.9	2.39		
92	Yamagishi 2008 19061714	SD 0.28	HR	nd	nd	nd	1.34	0.82	2.19		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
93	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Cholesterol ester	Yes
94	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Cholesterol ester	Yes
95	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Phospholipid	Yes
96	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Phospholipid	Yes
97	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Phospholipid	Yes
98	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Phospholipid	Yes
99	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	All	87/1684 (5.17)	14.3	EPA	Phospholipid	Yes
101 Subgroup analyses												
102	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	Age < 65	nd/337	4 y	DHA	Blood	No
103	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	Age ≥ 65	nd/375	4 y	DHA	Blood	No
104	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	LDL < 100	nd/164	4 y	DHA	Blood	No
105	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	LDL ≥ 100	nd/510	4 y	DHA	Blood	No
106	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	HDL < 40	nd/216	4 y	DHA	Blood	No
107	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	HDL ≥ 40	nd/449	4 y	DHA	Blood	No
108	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	Statin	nd/431	4 y	DHA	Blood	No
109	Hara 2013 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI patients	No Statin	nd/281	4 y	DHA	Blood	No
110	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	Male	nd/554	4 y	EPA	Blood	No
111	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	Female	nd/158	4 y	EPA	Blood	No
112	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	HDL < 40	nd/216	4 y	EPA	Blood	No
113	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	HDL ≥ 40	nd/449	4 y	EPA	Blood	No
114	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	Statin	nd/431	4 y	EPA	Blood	No
115	Hara 2012 23047296	Osaka Acute Coronary Insufficiency Study	CHF	Heart Failure Hospitalization	CVD	AMI Patients	No statin	nd/281	4 y	EPA	Blood	No

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
93	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	0.696832144
94	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	0.908834438
95	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.17553453
96	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.402679846
97	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean	0.56
98	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	0.717320154
99	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	0.94446547
101 Subgroup analyses						
102	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
103	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
104	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
105	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
106	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
107	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
108	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
109	Hara 2013 23047296	No	T1 vs. T2-3	nd	nd	nd
110	Hara 2012 23047296	No	T1 vs. T2-3	nd	nd	nd
111	Hara 2012 23047296	No	T1 vs. T2-3	nd	nd	nd
112	Hara 2012 23047296	No	T1 vs. T2-3	nd	nd	nd
113	Hara 2012 23047296	No	T1 vs. T2-3	nd	nd	nd
114	Hara 2012 23047296	No	T1 vs. T2-3	nd	nd	nd
115	Hara 2012 23047296	No	T1 vs. T2-3	nd	nd	nd

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
93	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.29	0.79	2.09		
94	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.29	0.78	2.12		
95	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.15
96	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.42	0.86	2.35		
97	Yamagishi 2008 19061714	SD 0.30	HR	nd	nd	nd	1.43	0.85	2.4		
98	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.51	0.92	2.48		
99	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.47	0.87	2.47		
101	Subgroup analyses										
102	Hara 2013 23047296	nd	nd	nd	nd	nd	0.52	0.11	2.41	Age interaction	0.051
103	Hara 2013 23047296	nd	nd	nd	nd	nd	3	1.31	6.85		
104	Hara 2013 23047296	nd	nd	nd	nd	nd	3.48	1.21	10.02	LDL interaction	0.0678
105	Hara 2013 23047296	nd	nd	nd	nd	nd	0.88	0.31	2.46		
106	Hara 2013 23047296	nd	nd	nd	nd	nd	4.5	1.16	17.4	HDL interaction	0.0962
107	Hara 2013 23047296	nd	nd	nd	nd	nd	1.17	0.5	2.77		
108	Hara 2013 23047296	nd	nd	nd	nd	nd	0.74	0.28	1.95	Statin interaction	0.003
109	Hara 2013 23047296	nd	nd	nd	nd	nd	6.65	2.31	19.15		
110	Hara 2012 23047296	nd	nd	nd	nd	nd	5.82	2.29	14.75	Sex interaction	0.0081
111	Hara 2012 23047296	nd	nd	nd	nd	nd	0.69	0.19	2.57		
112	Hara 2012 23047296	nd	nd	nd	nd	nd	15.68	1.99	123.8	HDL interaction	0.0344
113	Hara 2012 23047296	nd	nd	nd	nd	nd	1.44	0.62	3.33		
114	Hara 2012 23047296	nd	nd	nd	nd	nd	1.45	0.58	3.6	Statin interaction	0.0482
115	Hara 2012 23047296	nd	nd	nd	nd	nd	6.4	2.06	19.86		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
116	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	CVD	Healthy Swedish Men	Men with history of MI or DM at baseline	nd/5234	7 y	EPA+DHA	Intake	No
117	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	CVD	Healthy Swedish Men	Men with history of MI or DM at baseline	nd/5234	7 y	EPA+DHA	Intake	No
118	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	CVD	Healthy Swedish Men	Men with history of MI or DM at baseline	nd/5234	7 y	EPA+DHA	Intake	No
119	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	CVD	Healthy Swedish Men	Men with history of MI or DM at baseline	nd/5234	7 y	EPA+DHA	Intake	No
120	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	CVD	Healthy Swedish Men	Men with history of MI or DM at baseline	nd/5234	7 y	EPA+DHA	Intake	No
121	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline	563/39367 (1.43)	7 y	EPA+DHA	Intake	No
122	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline	563/39367 (1.43)	7 y	EPA+DHA	Intake	No
123	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline	563/39367 (1.43)	7 y	EPA+DHA	Intake	No
124	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline	563/39367 (1.43)	7 y	EPA+DHA	Intake	No
125	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline	563/39367 (1.43)	7 y	EPA+DHA	Intake	No

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
116	Levitan 2009 19383731	nd	Qt1	nd	nd	nd
117	Levitan 2009 19383731	nd	Qt2	nd	nd	nd
118	Levitan 2009 19383731	nd	Qt3	nd	nd	nd
119	Levitan 2009 19383731	nd	Qt4	nd	nd	nd
120	Levitan 2009 19383731	nd	Qt5	nd	nd	nd
121	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt1	nd	0.01	0.15
122	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt2	nd	0.24	0.27
123	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt3	nd	0.32	0.36
124	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt4	nd	0.41	0.46
125	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt5	nd	0.55	0.71

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
116	Levitan 2009 19383731	nd	HR	nd	nd	nd	Reference group				NS (implied)
117	Levitan 2009 19383731	nd	HR	nd	nd	nd	1.04	0.72	1.48		
118	Levitan 2009 19383731	nd	HR	nd	nd	nd	0.87	0.58	1.28		
119	Levitan 2009 19383731	nd	HR	nd	nd	nd	1.12	0.77	1.62		
120	Levitan 2009 19383731	nd	HR	nd	nd	nd	1.3	0.92	1.83		
121	Levitan 2009 19383731	0.22	HR	144	nd	52920	Reference group				NS (implied)
122	Levitan 2009 19383731	0.31	HR	122	nd	53340	0.94	0.74	1.2		
123	Levitan 2009 19383731	0.4	HR	74	nd	53666	0.67	0.5	0.9		
124	Levitan 2009 19383731	0.54	HR	102	nd	53553	0.89	0.68	1.16		
125	Levitan 2009 19383731	8.54	HR	155	nd	52623	1	0.77	1.29		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
126	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline, with supplement	563/39367 (1.43)	7y	EPA+DHA	Intake	Yes
127	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline, with supplement	563/39367 (1.43)	7y	EPA+DHA	Intake	Yes
128	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline, with supplement	563/39367 (1.43)	7y	EPA+DHA	Intake	Yes
129	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline, with supplement	563/39367 (1.43)	7y	EPA+DHA	Intake	Yes
130	Levitan 2009 19383731	Cohort of Swedish Men	CHF	nd	Healthy	Healthy Swedish Men	Men with no history of MI or DM at baseline, with supplement	563/39367 (1.43)	7y	EPA+DHA	Intake	Yes
131	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Cholesterol ester	Yes
132	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Cholesterol ester	Yes
133	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Cholesterol ester	Yes

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
126	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt1	nd	nd	nd
127	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt2	nd	nd	nd
128	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt3	nd	nd	nd
129	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt4	nd	nd	nd
130	Levitan 2009 19383731	body mass index, physical activity, energy, alcohol, fibre, sodium, and red or processed meat consumption, education, family history of myocardial infarction at ,60 years, cigarette smoking, marital status, self-reported history of hypertension, and high cholesterol.	Qt5	nd	nd	nd
131	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% FA	0.12	nd
132	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% FA	0.32	nd
133	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% FA	0.38	nd

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
126	Levitan 2009 19383731	nd	HR	nd	nd	nd	Reference group				NS (implied)
127	Levitan 2009 19383731	nd	HR	nd	nd	nd	0.99	0.77	1.27		
128	Levitan 2009 19383731	nd	HR	nd	nd	nd	0.73	0.54	0.97		
129	Levitan 2009 19383731	nd	HR	nd	nd	nd	0.97	0.75	1.27		
130	Levitan 2009 19383731	nd	HR	nd	nd	nd	1.05	0.82	1.36		
131	Yamagishi 2008 19061714	0.31	HR	nd	nd	nd	Reference group			P trend	0.001
132	Yamagishi 2008 19061714	0.37	HR	nd	nd	nd	0.58	0.31	1.08		
133	Yamagishi 2008 19061714	0.44	HR	nd	nd	nd	0.48	0.25	0.94		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
134	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Cholesterol ester	Yes
135	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Cholesterol ester	Yes
136	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Phospholipid	Yes
137	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Phospholipid	Yes
138	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Phospholipid	Yes
139	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Phospholipid	Yes
140	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	DHA	Phospholipid	Yes
141	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Cholesterol ester	Yes
142	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Cholesterol ester	Yes
143	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Cholesterol ester	Yes
144	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Cholesterol ester	Yes
145	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Cholesterol ester	Yes
146	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Phospholipid	Yes

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
134	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% FA	0.45	nd
135	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% FA	0.55	nd
136	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% FA	0	nd
137	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% FA	2.12	nd
138	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% FA	2.48	nd
139	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% FA	2.88	nd
140	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% FA	3.44	nd
141	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.23495175
142	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.356095918
143	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean (all)	0.44
144	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	0.523904082
145	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	0.64504825
146	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	1.669419107

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
134	Yamagishi 2008 19061714	0.54	HR	nd	nd	nd	0.47	0.24	0.91		
135	Yamagishi 2008 19061714	1.6	HR	nd	nd	nd	0.25	0.11	0.56		
136	Yamagishi 2008 19061714	2.11	HR	nd	nd	nd	Reference group			P trend	<0.001
137	Yamagishi 2008 19061714	2.47	HR	nd	nd	nd	0.83	0.45	1.55		
138	Yamagishi 2008 19061714	2.87	HR	nd	nd	nd	0.57	0.29	1.09		
139	Yamagishi 2008 19061714	3.43	HR	nd	nd	nd	0.51	0.26	0.99		
140	Yamagishi 2008 19061714	8.88	HR	nd	nd	nd	0.21	0.08	0.57		
141	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.26
142	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.03	0.57	1.88		
143	Yamagishi 2008 19061714	SD 0.16	HR	nd	nd	nd	0.93	0.49	1.77		
144	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.94	0.51	1.76		
145	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.54	0.85	2.79		
146	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.37

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
147	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Phospholipid	Yes
148	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Phospholipid	Yes
149	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Phospholipid	Yes
150	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	DHA	Phospholipid	Yes
151	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
152	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
153	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
154	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
155	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
156	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Phospholipid	Yes
157	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Phospholipid	Yes
158	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Phospholipid	Yes
159	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Phospholipid	Yes

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
147	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	2.343283544
148	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean (all)	2.81
149	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	3.276716456
150	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	3.950580893
151	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.500194889
152	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.7954838
153	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean (all)	1
154	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	1.2045162
155	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	1.499805111
156	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	2.857477762
157	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	3.697915431
158	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean (all)	4.28
159	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	4.862084569

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
147	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.77	0.42	1.4		
148	Yamagishi 2008 19061714	SD 0.89	HR	nd	nd	nd	1.03	0.54	1.96		
149	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.92	0.5	1.68		
150	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.24	0.68	2.26		
151	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.32
152	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.97	0.51	1.82		
153	Yamagishi 2008 19061714	SD 0.39	HR	nd	nd	nd	1.49	0.82	2.69		
154	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.71	0.35	1.42		
155	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.65	0.92	2.98		
156	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.2
157	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.73	0.39	1.38		
158	Yamagishi 2008 19061714	SD 1.11	HR	nd	nd	nd	1.05	0.56	1.96		
159	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.33	0.75	2.36		

Observational results: congestive heart failure

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure	Supplement
160	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	men	87/1684 (5.17)	14.3	EPA+DHA+DPA	Phospholipid	Yes
161	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
162	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
163	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
164	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
165	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Cholesterol ester	Yes
166	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Phospholipid	Yes
167	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Phospholipid	Yes
168	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Phospholipid	Yes
169	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Phospholipid	Yes
170	Yamagishi 2008 19061714	Atherosclerosis Risk in Communities Study	CHF	heart failure	Healthy	white aged 45-64, free of CHD, stroke and HF	women	110/1908 (5.77)	14.3	EPA+DHA+DPA	Phospholipid	Yes

Observational results: congestive heart failure

Row	Study PMID	Adjustments	Quantile	n3 units	Quantile low	Quantile median
160	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	5.702522238
161	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	0.500194889
162	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	0.7954838
163	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean (all)	1
164	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	1.2045162
165	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	1.499805111
166	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt1	% of total FA	Est 10% normal	2.857477762
167	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt2	% of total FA	Est 30% normal	3.697915431
168	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt3	% of total FA	Reported mean (all)	4.28
169	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt4	% of total FA	Est 70% normal	4.862084569
170	Yamagishi 2008 19061714	age, sex, body mass index, systolic blood pressure, antihypertensive medication use, plasma total and HDL cholesterol, diabetes, smoking status, cigarette-years, ethanol and energy intake, education level and sports index	Qt5	% of total FA	Est 90% normal	5.702522238

Observational results: congestive heart failure

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
160	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.16	0.63	2.13		
161	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.14
162	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.79	0.37	1.68		
163	Yamagishi 2008 19061714	SD 0.39	HR	nd	nd	nd	1.07	0.55	2.1		
164	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.05	0.54	2.05		
165	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.44	0.19	1.02		
166	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	Reference group			P trend	0.002
167	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	1.1	0.6	2.02		
168	Yamagishi 2008 19061714	SD 1.11	HR	nd	nd	nd	0.58	0.29	1.18		
169	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.49	0.24	0.98		
170	Yamagishi 2008 19061714	nd	HR	nd	nd	nd	0.37	0.16	0.84		